Firefly Neuroscience (AIFF)
FDA-cleared EEG assessment systems and brain-function reports for clinicians and drug developers.
Something off on this page? Send us feedback.
Provides FDA-cleared EEG and event-related-potential assessment systems that turn standardized recordings into clinician-facing brain-function reports, while serving pharmaceutical research partners. Revenue comes from equipment-linked subscriptions, assessments, sales, rentals, services, and projects through a single core platform concentrated primarily in North America.
Combines the FDA-cleared Evoke System and Brain Network Analytics platform to capture EEG and event-related-potential data, compare it with standardized reference data, and produce structured reports that complement clinical evaluation, treatment planning, and longitudinal management. Sales reach healthcare professionals in neurology, psychiatry, transcranial magnetic stimulation, and cognitive care, alongside pharmaceutical collaborators supporting neuroscience drug development.
Generates revenue through equipment-linked subscriptions, per-assessment fees, equipment sales and rentals, projects or clinical studies, and related services. The Firefly Products segment uses one core software platform and derives revenue primarily in North America. Commercialization depends on use within FDA-cleared claims, health-data and privacy compliance, database quality, cloud availability, and continued clinical-site and pharmaceutical-project activity.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.2M · Total debt $0 · Total assets $16.8M · Shareholders' equity $14.7M
- Revenue
- $514.0K
- Operating income
- −$2.0M
- Net income
- −$2.0M
No dividends on record.
| Institutions | 10.93% | 1.62M shares | |
|---|---|---|---|
| 22 holders · as of Jun 30, 2026 | |||
| Insiders | 11.51% | 1.70M shares | |
| 5 holders · as of Mar 13, 2026 | |||
| Strategic holders | 8.36% | 1.24M shares | |
| 1 holder · as of Oct 22, 2025 | |||
| Other | 69.20% | 10.24M shares | |
| remainder | |||
14.79M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Windsor Private Capital LPStrategic10 percent owner | 8.36% | 1.24M | filed Oct 22, 2025 |
Gregory LipschitzInsiderdirector, officer: Interim CEO | 6.31% | 933,891 | filed Mar 13, 2026 |
Murchinson Ltd.Institution | 4.39% | 650,000 | as of Jun 30, 2026 |
David Ian JohnsonInsiderdirector, officer: Executive Chairman | 3.77% | 557,885 | filed Oct 24, 2024 |
BlackRock, Inc.Institution | 1.27% | 187,168 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 22, 2025 | Windsor Private Capital LP | 10 percent owner | −78,031 | $2.07 |
| Oct 21, 2025 | Windsor Private Capital LP | 10 percent owner | −19,222 | $2.40 |
| Oct 20, 2025 | Windsor Private Capital LP | 10 percent owner | −33,500 | $2.46 |
| Oct 17, 2025 | Windsor Private Capital LP | 10 percent owner | −45,036 | $2.55 |
| Oct 16, 2025 | Windsor Private Capital LP | 10 percent owner | −40,139 | $2.65 |
- Compass Minerals
Broad clinical and research EEG-system overlap.
- Ceribell
Rapid EEG and AI interpretation overlap in acute care.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Firefly Neuroscience | $1.16 | −3.33% | $17.8M | — | — | 9.9 | +71.9% |
| Compass Minerals | $23.37 | −1.83% | $998.6M | 55.3 | 19.0 | 0.8 | +0.3% |
| Ceribell | $24.15 | −0.41% | $920.1M | — | — | 9.0 | +32.5% |
| Median | 55.3 | 19.0 | 4.9 | +16.4% |